GIPR agonism and antagonism both reduced weight in obese mice, but through distinct mechanisms: agonism improved glucose tolerance independently of weight loss while antagonism reduced appetite more sustainably but worsened insulin sensitivity.
Opposite actions, same weight lossBoth activating and blocking the GIP receptor reduced body weight in obese mice, but via distinct metabolic pathways
What the researchers found
Both GIPR agonism and antagonism reduced weight via decreased food intake in obese mice, but with distinct metabolic profiles: the agonist improved glucose tolerance independently of weight loss, while the antagonist produced more sustained appetite suppression but reduced insulin sensitivity.
Why it matters
Understanding why both activation and blockade of the GIP receptor cause weight loss is crucial for designing optimal next-generation obesity and diabetes drugs. These distinct mechanisms suggest different patients may benefit from different approaches.
How the study worked
Preclinical comparison study in lean and diet-induced obese male mice evaluating GIP108 (agonist) vs NN-GIPR-Ant (antagonist) on food intake, body weight, glucose/insulin tolerance, liver triglycerides, bone markers, and adipose gene expression, with pair-fed controls.
What this study cannot tell us
Male mice only—sex differences in GIP signaling are known. Lean mice showed minimal effects, limiting translatability. Short-term study may miss long-term metabolic consequences. Mouse physiology doesn't perfectly predict human responses.
How to read the evidence
Well-controlled preclinical study with pair-fed controls enabling mechanistic insights. Results informative for drug development but require human validation.
When this study was published
Published in 2025, directly addressing the ongoing GIP agonism vs antagonism debate in metabolic drug development.
The bigger picture
This study helps resolve the GIP paradox—how both agonism and antagonism can reduce weight. The answer lies in their distinct metabolic mechanisms, which has direct implications for personalizing incretin-based therapies.
Questions still open
- Would a combined GIP agonist/antagonist approach with a GLP-1 agonist produce better outcomes than either alone?
- Do female mice respond differently to GIPR agonism vs antagonism?
- Can the glucose tolerance benefits of GIPR agonism be separated from GIP's effects on fat storage?
Common questions
How can both activating and blocking the same receptor cause weight loss?
Does this affect drugs like tirzepatide?
Read the original research
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.
Diabetes, obesity & metabolism, 28(2), 1160-1167
Citation
Davies, Iona; Turland, Alexandra; Tran, Hanh Duyen; Wong, Carissa; Cahn, Olivier; Dunsterville, Cecilia; Sun, Yichang; Xiao, Yilin; Murphy, Kevin G; Bloom, Stephen R; Jones, Ben; Tan, Tricia M M. (2026). A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice.. Diabetes, obesity & metabolism, 28(2), 1160-1167. https://doi.org/10.1111/dom.70300